ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Gallic acid alleviates omeprazole-induced depressive behavior and memory impairment.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gallic acid partially attenuates thiomersal-associated oxidative, apoptotic, and CREB/BDNF-related alterations in rat hippocampal and prefrontal cortex tissues and systemic inflammatory responses.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The study aims to evaluate the effect of various doses of gallic acid (GA) on omeprazole (OMZ)-induced depression, memory impairment, oxido-neuroinflammation, and altered serotonergic neurotransmission in the midbrain and cerebral cortex of rats. Forty-eight male rats were divided into six groups (n = 8): Veh (vehicle), Veh + GA (50 mg/kg/ml), Veh + GA (100 mg/kg/ml), OMZ (20 mg/kg/ml), OMZ + GA (50 mg/kg/ml), and OMZ + GA (100 mg/kg/ml). Animals received their respective treatment intraperitoneally, daily for 4 weeks. After that, behavioral analysis for depression and memory function was performed; then, animals were decapitated, and their brains were removed from skulls. Brain regions, i.e., midbrain and cerebral cortex, were isolated for various biochemical and neurochemical studies. Results showed that OMZ-induced depression-like behavior and memory impairment were attenuated by GA in a dose-dependent manner. OMZ instigated decreased antioxidant enzyme activity and serotonergic mechanism, and increased oxido-neuroinflammation and acetylcholinesterase (AChE) activity were normalized by dose-dependent GA administration in both regions. In silico study also showed that GA has a potent antioxidant effect on the brain. In conclusion, the present findings revealed that GA, as a potential agent that reduced PPIs, induced depression-like behavior and memory impairment. The supplementation of GA as a dietary constituent could provide relief against OMZ-induced negative effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.